4DMedical Advances Respiratory Imaging Technology with University Partnership Extension and AI Development Grant
核心洞察
4DMedical (搜索) renewed its three-year contract with University of Michigan Medical Center (搜索), valued at approximately AUD$155,000, to provide access to advanced lung analysis applications through 2028.
A recent multicentre study published in Respiratory Research demonstrated that 4DMedical (搜索)'s XV LVAS (搜索)® technology can detect early small airways disease (搜索) often missed by standard diagnostic tests.
The company secured AUD$1.1 million in government funding through Australia's Economic Accelerator program to develop AI-derived functional biomarkers for enhanced respiratory disease diagnosis and treatment.
4DMedical (搜索) Limited has strengthened its position in respiratory imaging technology through a contract renewal with the University of Michigan Medical Center (搜索) and secured significant government funding to advance artificial intelligence applications in lung disease diagnosis.
The Australian company announced the renewal of its three-year contract with the University of Michigan Medical Center (搜索), valued at approximately AUD$155,000, running from July 1, 2025, to June 30, 2028. The agreement provides the university's clinicians and researchers access to 4DMedical (搜索)'s comprehensive suite of structural lung analysis applications, including LDAi, LDAf, PHA, and investigational use of LTA, delivered through the Enterprise Core Computing Platform.
Clinical Validation in Veterans Study
Supporting the technology's clinical utility, a recent multicentre study published in Respiratory Research highlighted the diagnostic capabilities of 4DMedical (搜索)'s X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS (搜索)®). The study, conducted among U.S. Veterans, demonstrated that XV LVAS® can detect early and subtle forms of small airways disease (搜索) that are frequently missed by standard diagnostic tests.
Researchers found that XV Technology (搜索)® successfully identifies disease-specific and severity-specific biomarker patterns in chronic obstructive pulmonary disease (搜索) (COPD (搜索)), potentially enabling earlier intervention and more targeted treatment approaches for patients with respiratory conditions.
Government Funding for AI Development
4DMedical (搜索) has been awarded AUD$1.1 million in non-dilutive cash funding under Round 1 of Australia's Economic Accelerator (AEA) Innovate grant program. The project is led by the University of Adelaide in partnership with 4DMedical, the University of Melbourne, and the Australian Institute for Machine Learning (搜索).
The funding will support the development of novel AI-derived functional biomarkers using XV Technology (搜索)® to enhance respiratory disease diagnosis and treatment capabilities. This initiative represents a significant step toward making advanced respiratory imaging technology more accessible and impactful on a global scale.
Leadership Perspective
Andreas Fouras, 4DMedical (搜索)'s MD/CEO and Founder, expressed enthusiasm for both developments, stating that the biomarkers derived from XV LVAS (搜索)® findings are "game-changing for pulmonary imaging." He emphasized that the AEA grant will accelerate the company's progress in making its technology more accessible and impactful globally.
The combination of continued academic partnerships and government-supported research positions 4DMedical (搜索) to advance respiratory imaging capabilities while expanding the clinical applications of its proprietary XV Technology (搜索)® platform.